Dr. Arun Srivastava is Professor in the Division of Cellular & Molecular Therapy in the Departments of Pediatrics, and Molecular Genetics & Microbiology, and Powell Gene Therapy Center at the University of Florida College of Medicine, in Gainesville, Florida, USA.

He has worked with AAV and AAV vectors for more than 44 years.

He has published 223 peer-reviewed research articles, book chapters, reviews, and miscellaneous articles, and 264 abstracts.

He was the founding scientist of the very first AAV gene therapy company, Avigen, which was launched in 1992. He was also a co-founder of a second AAV gene therapy company, Lacerta Therapeutics, which was launched in 2017. In 2023, he founded a third AAV gene therapy company, sAAVient Therapeutics, and a fourth AAV gene editing company, nAAVigen Therapeutics, in 2024.